(Bloomberg) -- The stock market’s recent wipeout has pushed a quarter of biotechnology stocks to trade below their cash holdings. That’s left bargain-hunters with a choice: Buy the dip or sit this one ...

Fortress Biotech is trading below its cash balance, offering deep value relative to its assets and financial improvements.

Why do CEOs talk like that? Do biotech stock tips make good gifts? And what do Anthony Fauci and Stéphane Bancel have in common? We cover all that and more this week on “The Readout LOUD,” STAT’s ...

Zhengye receives a Nasdaq notice for failing to file its 2024 annual report on time. The company has 60 days to submit a compliance plan to avoid potential delisting. Get special access to three ...

Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.

Buffett’s casino comments raise an uncomfortable truth. Is biotechnology an investment, or is it more of a gambling casino?

Vir Biotechnology is rated a buy, supported by a strong cash position, pivotal late-stage pipeline, and deep institutional backing. VIR's lead CHD drugs, Tobevibart and Elebsiran, target a large, ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...

TheFly reported on June 3 that UBS increased its price target on LEGN to $49 from $31 while reiterating a Buy rating on the stock. The U.S. healthcare sector has significantly lagged the broader ...

Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update. Trading of Shanghai Henlius Biotech, Inc.’s H shares has been temporarily halted as of 9:00 a.m. on May 23, 2024, in ...